# A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01316887** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 563 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** 125/25 mcg once-daily GSK573719/GW642444
- **DRUG:** 125mcg once-daily GSK573719
- **DRUG:** Placebo once-daily

## Key facts

- **NCT ID:** NCT01316887
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2012-07-01
- **Final completion:** 2012-07-21
- **Target enrollment:** 563 (ACTUAL)
- **Last updated:** 2018-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316887, "A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01316887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*